Diabetic Retinopathy (DR)

Sponsor - aerpio (Recruiting/Open to Enrollment)

Study: TIME-2b
PHASE 2 DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF SUBCUTANEOUSLY ADMINISTERED AKB-9778 15 MG ONCE DAILY OR 15 MG TWICE DAILY FOR 12 MONTHS IN PATIENTS WITH MODERATE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY
https://clinicaltrials.gov/ct2/show/NCT03197870?term=TIME-2b&recrs=ab&rank=1

Sponsor – Regeneron (Closed to Enrollment)

Study: PANORAMA
A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY
https://clinicaltrials.gov/ct2/show/NCT02718326?term=PANORAMA&rank=3​

Previous Diabetic Retinopathy (DR) Study:

Sub-Investigator, 2007 - 2009
Protocol FVF4296s: An Open-Label Study to Determine the Dynamics of Regression of Neovascularization in Proliferative Diabetic Retinopathy Following Treatment with Intravitreal Ranibizumab.